Kun He Lee1, Vasileios-Arsenios Lioutas2, Sarah Marchina2, Magdy Selim2. 1. Stroke Division, Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA, USA. khlee@bidmc.harvard.edu. 2. Stroke Division, Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA, USA.
Abstract
BACKGROUND: Conflicting data exist regarding the association of perihematomal edema (PHE) with outcomes after intracerebral hemorrhage (ICH). We performed a post hoc analysis of the ICH Deferoxamine trial to examine whether an early change in ventricular size (VS), as a composite measure of PHE growth and mass effect, intraventricular hemorrhage, and hydrocephalus, is a more accurate predictor of outcome than PHE measures alone. METHODS: Computerized tomography scans were performed at baseline and after 72-96 h. We evaluated measures of PHE and change in VS as predictors of outcome, assessed by a dichotomized modified Rankin Scale score (0-2 versus 3-6), primarily at 90 days and secondarily at 30 days. A multivariable logistic regression model was fitted for each predictor, with adjustment for the same confounders. RESULTS: A total of 248 participants were included after we excluded those requiring external ventricular drains. On univariate analyses, older age, female sex, lower Glasgow Coma Scale score and baseline temperature, greater ICH volume, absolute PHE volume, edema extension distance at presentation, lesser changes in relative PHE volume and edema extension distance, and an increase in VS were associated with poor outcome. In multivariable analyses, only the increase in VS was associated with lower odds of modified Rankin Scale scores 0-2 at 90 days (odds ratio 0.927, 95% confidence interval 0.866-0.970, p = 0.001) and 30 days (odds ratio 0.931, 95% confidence interval 0.888-0.975, p = 0.003). CONCLUSIONS: Within the context of a randomized controlled trial with standardized imaging and functional assessments, we did not find significant associations between measures of PHE and outcome but documented an independent association between early increase in VS and lower odds of good clinical outcome.
BACKGROUND: Conflicting data exist regarding the association of perihematomal edema (PHE) with outcomes after intracerebral hemorrhage (ICH). We performed a post hoc analysis of the ICH Deferoxamine trial to examine whether an early change in ventricular size (VS), as a composite measure of PHE growth and mass effect, intraventricular hemorrhage, and hydrocephalus, is a more accurate predictor of outcome than PHE measures alone. METHODS: Computerized tomography scans were performed at baseline and after 72-96 h. We evaluated measures of PHE and change in VS as predictors of outcome, assessed by a dichotomized modified Rankin Scale score (0-2 versus 3-6), primarily at 90 days and secondarily at 30 days. A multivariable logistic regression model was fitted for each predictor, with adjustment for the same confounders. RESULTS: A total of 248 participants were included after we excluded those requiring external ventricular drains. On univariate analyses, older age, female sex, lower Glasgow Coma Scale score and baseline temperature, greater ICH volume, absolute PHE volume, edema extension distance at presentation, lesser changes in relative PHE volume and edema extension distance, and an increase in VS were associated with poor outcome. In multivariable analyses, only the increase in VS was associated with lower odds of modified Rankin Scale scores 0-2 at 90 days (odds ratio 0.927, 95% confidence interval 0.866-0.970, p = 0.001) and 30 days (odds ratio 0.931, 95% confidence interval 0.888-0.975, p = 0.003). CONCLUSIONS: Within the context of a randomized controlled trial with standardized imaging and functional assessments, we did not find significant associations between measures of PHE and outcome but documented an independent association between early increase in VS and lower odds of good clinical outcome.
Authors: S M Davis; J Broderick; M Hennerici; N C Brun; M N Diringer; S A Mayer; K Begtrup; T Steiner Journal: Neurology Date: 2006-04-25 Impact factor: 9.910
Authors: Anirudh Sreekrishnan; Jennifer L Dearborn; David M Greer; Fu-Dong Shi; David Y Hwang; Audrey C Leasure; Sonya E Zhou; Emily J Gilmore; Charles C Matouk; Nils H Petersen; Lauren H Sansing; Kevin N Sheth Journal: Neurocrit Care Date: 2016-12 Impact factor: 3.210
Authors: Magdy Selim; Lydia D Foster; Claudia S Moy; Guohua Xi; Michael D Hill; Lewis B Morgenstern; Steven M Greenberg; Michael L James; Vineeta Singh; Wayne M Clark; Casey Norton; Yuko Y Palesch; Sharon D Yeatts Journal: Lancet Neurol Date: 2019-03-18 Impact factor: 44.182
Authors: Santosh B Murthy; Yogesh Moradiya; Jesse Dawson; Kennedy R Lees; Daniel F Hanley; Wendy C Ziai Journal: Stroke Date: 2015-09-22 Impact factor: 7.914
Authors: Zachary Grunwald; Lauren A Beslow; Sebastian Urday; Anastasia Vashkevich; Alison Ayres; Steven M Greenberg; Joshua N Goldstein; Audrey Leasure; Fu-Dong Shi; Kristopher T Kahle; Thomas W K Battey; J Marc Simard; Jonathan Rosand; W Taylor Kimberly; Kevin N Sheth Journal: Neurocrit Care Date: 2017-04 Impact factor: 3.210
Authors: Sebastian S Roeder; Maximilian I Sprügel; Jochen A Sembill; Antje Giede-Jeppe; Kosmas Macha; Dominik Madžar; Hannes Lücking; Philip Hoelter; Stefan T Gerner; Joji B Kuramatsu; Hagen B Huttner Journal: Cerebrovasc Dis Date: 2019-06-18 Impact factor: 2.762
Authors: Candice Delcourt; Yining Huang; Hisatomi Arima; John Chalmers; Stephen M Davis; Emma L Heeley; Jiguang Wang; Mark W Parsons; Guorong Liu; Craig S Anderson Journal: Neurology Date: 2012-06-27 Impact factor: 9.910